Search

Your search keyword '"Azim, Hatem A."' showing total 12 results
Start Over Author "Azim, Hatem A." Database OpenAIRE
12 results on '"Azim, Hatem A."'

1. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Author

Lambertini, Matteo, Martel, Samuel, Campbell, Christine, Guillaume, Sébastien, Hilbers, Florentine, Schuehly, Uwe, Korde, Larissa, Azim, Hatem, Di Cosimo, Serena, Tenglin, Richard, Huober, Jens, Baselga, José, Moreno-Aspitia, Alvaro, Piccart-Gebhart, Martine, Gelber, Richard, De Azambuja, Evandro, Ignatiadis, Michail, Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Université libre de Bruxelles (ULB), Université de Sherbrooke (UdeS), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Novartis Pharma AG, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), American University of Beirut [Beyrouth] (AUB), Human Tumor Immunobiology Unit [Fondazione IRCCS Istituto Nazionale dei Tumori, Milan], Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Universitätsklinikum Ulm - University Hospital of Ulm, Memorial Sloane Kettering Cancer Center [New York], Mayo Clinic [Jacksonville], Dana-Farber Cancer Institute [Boston], Harvard Medical School [Boston] (HMS), Harvard T.H. Chan School of Public Health, Michel-Avella, Amandine, and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Cancer Research, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, breast cancer, human epidermal growth factor receptor 2 (HER2)–positive, lapatinib, pregnancy, survivorship, trastuzumab, young patients, Oncology, Cancer Research, human epidermal growth factor receptor 2 (HER2)–positive, young patients, trastuzumab, breast cancer, Oncology, pregnancy, lapatinib, skin and connective tissue diseases, survivorship, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, human epidermal growth factor receptor 2 (HER2)-positive
Abstract

International audience; BACKGROUND:Limited data exist on the safety of using anti-human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior early breast cancer, with no data in HER2-positive patients.METHODS:The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial and the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial were randomized phase 3 trials for patients with HER2-positive early breast cancer. In both trials, pregnancy information was prospectively collected. Pregnancy outcomes were compared between patients unintentionally exposed to trastuzumab and/or lapatinib during gestation (the exposed group) and those who became pregnant after trastuzumab and/or lapatinib completion (the unexposed group). In the ALTTO trial, disease-free survival (DFS) was compared between pregnant patients and those aged 40 years or younger without a subsequent pregnancy via an extended Cox model with time-varying covariates to account for a guarantee-time bias.RESULTS:Ninety-two patients (12 in the exposed group and 80 in the unexposed group) had a pregnancy: 7 in the NeoALTTO trial and 85 in the ALTTO trial. Seven patients (58.3%) in the exposed group and 10 patients (12.5%) in the unexposed group opted for an induced abortion; in the unexposed group, 10 patients (12.5%) had a spontaneous abortion. No pregnancy/delivery complications were reported for the remaining cases, who successfully completed their pregnancy, with the exception of 1 fetus with trisomy 21 (Down syndrome). No significant difference in DFS (adjusted hazard ratio, 1.12; 95% confidence interval, 0.52-2.42) was observed between young patients with a pregnancy (n = 85) and young patients without a pregnancy (n = 1307).CONCLUSIONS:For patients with HER2-positive early breast cancer, having a pregnancy after treatment completion appears to be safe without compromising fetal outcome or maternal prognosis.

Published
2019

3. Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors

Author

Azim, Hatem A., Pavlidis, Nicholas, Peccatori, Fedro A., Pavlidis, Nicholas [0000-0002-2195-9961], Peccatori, Fedro A. [0000-0001-8227-8740], and Azim, Hatem A. [0000-0003-4344-777X]

Subjects
Oncology, Hematologic malignancy, Dose-response relationship, Pancytopenia, Review, Acute lymphoblastic leukemia, Pregnancy, Antineoplastic agents, Treatment outcome, Drug safety, Melphalan, Hypospadias, Mercaptopurine, Chronic myeloid leukemia, Pregnancy Outcome, Burkitt lymphoma, General Medicine, Environmental exposure, Embryopathy, Antineoplastic agent, Promyelocytic leukemia, Vincristine, Cleft palate, Granulocyte colony stimulating factor, Hematologic Neoplasms, Nonhodgkin lymphoma, Immunotherapy, Safety, Rituximab, Zidovudine, Human, medicine.medical_specialty, Jaundice, Antineoplastic Agents, Bleomycin, Pregnancy outcome, Breast cancer, Human immunodeficiency virus infection, Dose response, Retinoic acid, Asparaginase, Humans, Cyclophosphamide, Spontaneous abortion, Heart atrium septum defect, Gynecology, Dose-Response Relationship, Drug, Enterocolitis, Cleft lip, Methodology, Tioguanine, Leukopenia, Growth retardation, medicine.disease, Cancer combination chemotherapy, Acute granulocytic leukemia, B cell lymphoma, Methotrexate, chemistry, Procarbazine, Imatinib, Blood disease, Disseminated intravascular clotting, Hemolytic anemia, Mitoxantrone, Idarubicin, Leukemia in pregnancy, Lymphoma in pregnancy, Down syndrome, Meningocele, chemistry.chemical_compound, Teratogenicity, Hydroxyurea, Pylorus stenosis, Hematologic neoplasms, Cervical cancer, Fetus death, Antibiotic agent, Cytarabine, Gastroenteritis, Dacarbazine, Treatment Outcome, Immunosuppressive agent, Lamivudine, Cancer radiotherapy, Female, Drug, Immunosuppressive agents, Pregnancy Complications, Neoplastic, Immunosuppressive Agents, Hydrocephalus, Hodgkin disease, Cardiomyopathy, Umbilical hernia, Vinblastine, Alpha interferon, Pregnancy complication, Internal medicine, medicine, Chemotherapy, Radiology, Nuclear Medicine and imaging, Lung cancer, Busulfan, Fetus distress, Neoplastic, business.industry, Daunorubicin, Chlormethine, Cancer, Drug efficacy, Polydactyly, Pregnancy complications, Doxorubicin, Systematic review, Thumb malformation, Prednisone, Congenital malformation, Warfarin, Unindexed drug, Ovarian cancer, business
Abstract

The association of cancer and pregnancy is increasingly encountered nowadays in clinical practice. Due to the relative rarity of the situation, it lacks a systematized approach. Different systemic therapies are used in managing cancer with uncertainty regarding the potential hazards they could pose on the pregnancy and/or the fetus. We have performed a systematic review of literature to identify all reports addressing cancer patients who were exposed to any of the known systemic therapies during the course of the pregnancy. The results were discussed in two parts; part I addresses pregnant patients with solid tumors while part I for those with hematological malignancies. In part I, we identified different solid tumors diagnosed and treated during the course of pregnancy. Breast cancer was the most commonly treated followed by ovarian cancer. Other tumors were treated as well including lung cancer, cervical cancer, sarcoma and melanomas. It is important to acknowledge the intent of therapy (palliative vs. curative) and the patients has to be properly counseled to reach an informed decision. We aim to provide a more robust consensus on how to approach these cases and provide a higher degree of evidence to support the safety of applying certain management strategies over the other.

Published
2010

5. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Peccatori, Fedro A., Azim, Hatem A., Orecchia, R., Hoekstra, H. J., Pavlidis, Nicholas, Kesic, V., Pentheroudakis, George, Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462], Peccatori, Fedro A. [0000-0001-8227-8740], and Azim, Hatem A. [0000-0003-4344-777X]

Subjects
Oncology, Pelvis radiography, medicine.medical_treatment, Acute lymphoblastic leukemia, law.invention, Carboplatin, 0302 clinical medicine, Breast cancer, Pregnancy, Antineoplastic agents, Germ cell tumor, Drug safety, Fertility preservation, Melanoma, Mastectomy, media_common, Soft tissue sarcoma, 030219 obstetrics & reproductive medicine, OVARIAN STIMULATION, Systemic therapy, HORMONE AGONIST, Chronic myeloid leukemia, 3. Good health, Nuclear magnetic resonance imaging, Mental deficiency, Promyelocytic leukemia, OF-THE-LITERATURE, 030220 oncology & carcinogenesis, Cancer survivor, Nonhodgkin lymphoma, Cancer chemotherapy, Treatment indication, Human, medicine.medical_specialty, CERVICAL-CANCER, Uterine cervical neoplasms, Paclitaxel, media_common.quotation_subject, Antineoplastic Agents, Risk Assessment, Fetus monitoring, Article, Pregnancy outcome, 03 medical and health sciences, Retinoic acid, BREAST-CANCER, Humans, Fetal well being, medicine.disease, Intrauterine growth retardation, RANDOMIZED-TRIAL, Acute granulocytic leukemia, Drug contraindication, Imatinib, MONOCLONAL-ANTIBODIES, Cisplatin, Breast neoplasms, Cancer incidence, Pediatrics, Lymphoma, Partial mastectomy, Uterine Cervical Neoplasms, Segmental, Mastectomy, Segmental, Cancer staging, NEOADJUVANT CHEMOTHERAPY, Cancer surgery, Randomized controlled trial, Sentinel lymph node biopsy, law, Neoplasms, Female fertility, Priority journal, Risk assessment, Cervical cancer, Platinum derivative, Leukemia, Obstetric procedure, Lymphoma, Non-Hodgkin, Cytarabine, Cancer diagnosis, Hematology, GERM-CELL TUMORS, Hodgkin Disease, Europe, Lung non small cell cancer, SENTINEL NODE BIOPSY, Cancer radiotherapy, Female, Uterine cervix cancer, Childhood cancer, Pregnancy Complications, Neoplastic, Hodgkin disease, Ovary cancer, Fetus malformation, Breast Neoplasms, Fertility, Follow-up studies, Alpha interferon, Internal medicine, medicine, First trimester pregnancy, Neoplasm Staging, Neoplastic, Non-hodgkin, business.industry, Ovary carcinoma, Cancer, Gestational age, Malignant neoplastic disease, Pregnancy complications, Doxorubicin, Neoplasm staging, Ovary tumor, Germ cell tumors, business, Follow-Up Studies
Abstract

24 SUPPL.6 vi160 vi170

Published
2013

9. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies

Author

Jr, H. A. Azim, Santoro, L., Pavlidis, Nicholas, Gelber, S., Kroman, N., Azim, Hatem A., Peccatori, Fedro A., Pavlidis, Nicholas [0000-0002-2195-9961], Peccatori, Fedro A. [0000-0001-8227-8740], and Azim, Hatem A. [0000-0003-4344-777X]

Subjects
Cancer Research, Cancer relapse, Disease, Feasibility study, Breast cancer, Pregnancy, Epidemiology of cancer, Medicine, Overall survival, Priority journal, media_common, education.field_of_study, Obstetrics, Cancer diagnosis, Middle Aged, Patient safety, Pregnancy after breast cancer, Oncology, Meta-analysis, Female, Safety, Pregnancy Complications, Neoplastic, Human, Adult, Healthy mother effect, medicine.medical_specialty, media_common.quotation_subject, Population, Subgroup analysis, Fertility, Breast Neoplasms, Cancer mortality, Article, Pregnancy outcome, Humans, education, Pregnancy Complications, Neoplastic/*mortality, Aged, Neoplastic, Breast Neoplasms/*mortality, business.industry, medicine.disease, Pregnancy complications, Risk reduction, Counselling, Breast neoplasms, business, Epidemiologic Methods
Abstract

Background: Due to the rising trend of delaying pregnancy to later in life, more women are diagnosed with breast cancer before completing their families. Therefore, enquiry into the feasibility and safety of pregnancy following breast cancer diagnosis is on the rise. Available evidence suggests that women with a history of breast cancer are frequently advised against future conception for fear that pregnancy could adversely affect their breast cancer outcome. Hence, we conducted a meta-analysis to understand the effect of pregnancy on overall survival of women with a history of breast cancer. Methods: Two of the authors independently performed a literature search up to September 2009 with no language restrictions. Eligible studies were published retrospective control-matched, population-based and hospital-based studies that have addressed the impact of pregnancy on the overall survival of women with history of breast cancer. Pooling of data was done using the random effect model. Unpublished statistics from three studies were obtained to perform further subgroup and sensitivity analyses. This included examining the effect of pregnancy according to age at diagnosis, healthy mother effect, type of study, nodal status and other parameters. Results: Fourteen studies were included in this meta-analysis (1244 cases and 18,145 controls). Women who got pregnant following breast cancer diagnosis had a 41% reduced risk of death compared to women who did not get pregnant [PRR: 0.59 (90% confidence interval (CI): 0.50-0.70)]. This difference was seen irrespective of the type of the study and particularly in women with history of node-negative disease. In a subgroup analysis, we compared the outcome of women with history of breast cancer who became pregnant to breast cancer patients who did not get pregnant and were known to be free of relapse. In this analysis, we did not find significant differences in survival between either group [PRR: 0.85; 95% CI: 0.53-1.35]. Conclusions: This study confirms that pregnancy in women with history of breast cancer is safe and does not compromise their overall survival. Hence, breast cancer survivors should not be denied the opportunity of future conception. © 2010 Elsevier Ltd. All rights reserved. 47 1 74 83

Published
2010

10. Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors

Author

Azim, Hatem A., Peccatori, Fedro A., Pavlidis, Nicholas, Pavlidis, Nicholas [0000-0002-2195-9961], Peccatori, Fedro A. [0000-0001-8227-8740], and Azim, Hatem A. [0000-0003-4344-777X]

Subjects
Hypermetropia, Dose-response relationship, Review, Docetaxel, Clinical practice, Carboplatin, Breast cancer, Pregnancy, Antineoplastic agents, Drug safety, Disease free survival, Melanoma, Etoposide, Pregnancy Outcome, Sarcoma, General Medicine, Kidney polycystic disease, Oxaliplatin, Mental deficiency, Selective estrogen receptor modulator, Oncology, Antineoplastic agent, Erlotinib, Vincristine, Cleft palate, Bisphosphonic acid derivative, Immunotherapy, Lung cancer, Selective estrogen receptor modulators, Human, Selective Estrogen Receptor Modulators, Paclitaxel, Bicuspid aortic valve, Antineoplastic Agents, Irinotecan, Pregnancy outcome, Bleomycin, Idiopathic disease, Microphthalmia, Dose response, Humans, Cyclophosphamide, Spontaneous abortion, Dose-Response Relationship, Drug, Methodology, Kaposi sarcoma, Bone metastasis, Lapatinib, Colorectal cancer, Cancer combination chemotherapy, Brain tumor, Tamoxifen, Methotrexate, Procarbazine, Cisplatin, Physical disability, Down syndrome, Brachytherapy, Neuroblastoma, Teratogenicity, Lomustine, Neoplasms, Overall survival, Eclampsia, Drug tolerability, Fetus death, Platinum complex, Solid tumor, Vesicoureteral reflux, Folinic acid, Anemia, Dacarbazine, Clubfoot, Immunosuppressive agent, Female, Fluorouracil, Drug, Immunosuppressive agents, Uterine cervix cancer, Pregnancy Complications, Neoplastic, Immunosuppressive Agents, Ovary cancer, Navelbine, Adenoid cystic carcinoma, Vinblastine, Oligohydramnios, Head and neck tumor, Pregnancy complication, Temozolomide, Radiology, Nuclear Medicine and imaging, Epirubicin, Neoplastic, Hypocalcemia, Respiratory distress, Trastuzumab, Preeclampsia, Carmustine, Drug efficacy, Pregnancy complications, Doxorubicin, Systematic review, Prednisone, Neoplasm, Congenital malformation, Syndactyly, Unindexed drug
Abstract

The association of cancer and pregnancy is increasingly encountered nowadays in clinical practice. Due to the relative rarity of the situation, it lacks a systematized approach. Different systemic therapies are used in managing cancer with uncertainty regarding the potential hazards they could pose on the pregnancy and/or the fetus.We have performed a systematic review of literature to identify all reports addressing cancer patients who were exposed to any of the known systemic therapies during the course of the pregnancy. The results were discussed in two parts; part I addresses pregnant patients with solid tumors while part I for those with hematological malignancies.In part I, we identified different solid tumors diagnosed and treated during the course of pregnancy. Breast cancer was the most commonly treated followed by ovarian cancer. Other tumors were treated as well including lung cancer, cervical cancer, sarcoma and melanomas. It is important to acknowledge the intent of therapy (palliative vs. curative) and the patients has to be properly counseled to reach an informed decision.We aim to provide a more robust consensus on how to approach these cases and provide a higher degree of evidence to support the safety of applying certain management strategies over the other. © 2009 Elsevier Ltd. 36 2 101 109

Published
2010

12. Clinical behavior and outcomes of BRCA-mutated breast cancer in young patients according to type of BRCA mutation and hormone receptor status: Results from an international cohort study

Author

Lambertini, Matteo, Ceppi, Marcello, Anne-Sophie HAMY, Caron, Olivier, Poorvu, Philip D., Carrasco, Estela, Grinshpun, Albert, Punie, Kevin, Rousset-Jablonski, Christine, Ferrari, Alberta, Paluch-Shimon, Shani, Toss, Angela, Senechal, Claire, Puglisi, Fabio, Pogoda, Katarzyna, Perez-Fidalgo, Jose Alejandro, Marchis, Laura, Ponzone, Riccardo, Livraghi, Luca, Estevez-Diz, Maria Del Pilar, Villarreal-Garza, Cynthia, Dieci, Maria Vittoria, Clatot, Florian, Duhoux, Francois P., Graffeo, Rossella, Teixeira, Luis, Cordoba, Octavi, Sonnenblick, Amir, Ferreira, Arlindo R., Partridge, Ann H., Di Meglio, Antonio, Saule, Claire, Peccatori, Fedro A., Bruzzone, Marco, Del Mastro, Lucia, Ameye, Lieveke, Balmana, Judith, and Azim, Hatem A.

Catalog

Books, media, physical & digital resources
See catalog results